#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Dermatitis atopic Breast cancer metastatic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cystic fibrosis gastrointestinal disease Dedifferentiated liposarcoma Brain injury Antisynthetase syndrome Epileptic encephalopathy Inclusion body myositis Small for dates baby Hypotransferrinaemia Malignant melanoma Iron overload Leukocyte adhesion deficiency type I Pustular psoriasis Hairy cell leukaemia Noonan syndrome Cholangitis sclerosing More trials…

    Learn about Rare Diseases

    Lymphangioma – Trials in Disease Turner’s syndrome Propionic acidaemia – Basic Information Glomerulonephritis membranoproliferative – Life with Disease Wolfram syndrome – Life with Disease Mitochondrial myopathy – Diagnostics Lysosomal storage disorder – Basic Information Arterial tortuosity syndrome Uterine leiomyosarcoma – Treatment Chronic granulomatous disease – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Indacaterol ANHYDROUS CALCIUM FOLINATE INCB123667 Alternaria Alternata (402) Eptacog Beta (Activated) Histidine Afamelanotide Litenimod Sodium IADADEMSTAT Anakinra ICEF15 Fitusiran Hu5F9‐G4 Dalbavancin Mometasone Latozinemab Raxtozinameran Gsk6097608 Selgantolimod Sunitinib More therapies…

    Learn about Your Condition

    Glanzmann's disease Osteomyelitis acute Brain neoplasm malignant Immune-mediated enterocolitis Obstructive pancreatitis Herpes simplex Venous thrombosis limb Weaning failure Interstitial lung disease Incisional hernia Facial paresis Axial spondyloarthritis Haemofiltration Hypereosinophilic syndrome Thermal burn More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Szpital Uniwersytecki Nr 2 Im Dr Jana Biziela W Bydgoszczy…

Szpital Uniwersytecki Nr 2 Im Dr Jana Biziela W Bydgoszczy

Uhs Kjzzrep Ukhnvudyvv 7yx Bmrliywvcc 8nypcem Pepaug

Want to learn more about this study or check if you can participate? Contact us.

  • Phase 3 Study Comparing JNJ-79635322 with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma after 1‑3 Prior Treatments

    Recruiting

    3 1 1
    Investigated Drugs:
    • Teclistamab
    • IGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL RECEPTOR CD3, B-CELL MATURATION ANTIGEN AND G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D
    Czechia France Germany Greece Italy Poland +1

  • Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus

    Recruiting

    3 1
    Investigated Diseases:
    • Systemic lupus erythematosus
    Investigated Drugs:
    • Nipocalimab
    Bulgaria Czechia Denmark Finland France Germany +9

  • QTX-2101 and Arsenic Trioxide in Adult Patients With Acute Promyelocytic Leukemia

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Acute promyelocytic leukaemia
    Investigated Drugs:
    • Arsenic Trioxide
    France Germany Italy Poland Romania Spain

  • Tulisokibart for Psoriatic Arthritis in Adults

    Recruiting

    2 1
    Investigated Drugs:
    • Tulisokibart
    Germany Poland Spain

  • A study of acalabrutinib and venetoclax for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have relapsed after initial treatment

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Chronic lymphocytic leukaemia recurrent
    Investigated Drugs:
    • Acalabrutinib
    • Venetoclax
    Austria Czechia Ireland Italy Poland Spain

  • A study to evaluate the effectiveness and safety of JNJ-88545223 in people with active psoriatic arthritis

    Recruiting

    2 1
    Investigated Diseases:
    • Psoriatic arthropathy
    Czechia Germany Hungary Poland Spain

  • Evaluation of Long-Term Safety and Efficacy of Litifilimab in Adults with Active Systemic Lupus Erythematosus: A Phase 3 Multicenter, Randomized, Dose-Blind Study

    Recruiting

    3 1
    Investigated Diseases:
    • Systemic lupus erythematosus
    Investigated Drugs:
    • Litifilimab
    Belgium Bulgaria Czechia France Germany Greece +7

  • A study to evaluate the safety of dazodalibep in patients with Sjögren’s Syndrome over a long period of time

    Recruiting

    3 1 1
    Investigated Diseases:
    • Sjogren’s syndrome
    Investigated Drugs:
    • Dazodalibep
    Belgium Croatia Denmark France Germany Greece +6

  • A study of navenibart for long-term safety in patients with hereditary angioedema

    Recruiting

    3 1
    Investigated Diseases:
    • Hereditary angioedema
    • Hereditary angioedema with C1 esterase inhibitor deficiency
    Investigated Drugs:
    • NAVENIBART
    Austria Bulgaria Czechia France Germany Hungary +5

  • Study of Revumenib and Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia with NPM1 Gene Mutation

    Recruiting

    3 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Cytarabine
    • Daunorubicin Hydrochloride
    • Idarubicin Hydrochloride
    Austria Belgium Czechia France Germany Greece +7
1 2 3 … 12
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!